{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:35:05Z","timestamp":1783596905731,"version":"3.55.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,20]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fc\u03b3 receptor\u2013dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound mAbs trigger the complement cascade to deposit C3 activation fragments and lyse cells. Within 24 hours after ofatumumab administration to patients with chronic lymphocytic leukemia (CLL), circulating tumor cells had lost CD20 and were opsonized with C3d, the terminal covalently bound form of complement protein C3. We hypothesized that C3d provides a target to eliminate residual CD20\u2212 tumor cells. To test this hypothesis, we generated C8xi, a mouse\/human chimeric immunoglobulin G1 (IgG1) that reacts with human but not mouse C3d. C8xi was effective in a patient-derived xenograft model against CD20\u2212, C3d opsonized CLL cells from patients treated with ofatumumab. We also generated rabbit mAbs, 2 of which were chosen because they bound mouse and human C3d with low\u00a0nanomolar affinity but were minimally cross-reactive with full-length C3. Anti-C3d rabbit\/human chimeric IgG1 in combination with ofatumumab or rituximab prolonged survival of xenografted mice that model 3 different types of non-Hodgkin lymphoma (NHL). For example, in a diffuse large B-cell lymphoma model (SU-DHL-6), median survival with single-agent CD20 mAb was 114 days but was not reached for mAb combination treatment (P\u00a0=\u00a0.008). In another NHL model (SU-DHL-4), single-agent and combination mAb therapy eradicated lymphoma in most mice. In long-term survivors from both cohorts, there was no evidence of adverse effects. We propose that C3d mAbs combined with complement-fixing CD20 mAbs can overcome antigen-loss escape and increase efficacy of mAb-based therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024846","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:35:41Z","timestamp":1736285741000},"page":"1309-1320","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells"],"prefix":"10.1182","volume":"145","author":[{"given":"Sivasubramanian","family":"Baskar","sequence":"first","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-1337","authenticated-orcid":false,"given":"Haiyong","family":"Peng","sequence":"additional","affiliation":[{"name":"2Department of Immunology and Microbiology, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-3105","authenticated-orcid":false,"given":"Erika M.","family":"Gaglione","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"},{"name":"3Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7463-4696","authenticated-orcid":false,"given":"Elizabeth J.","family":"Carstens","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Lindorfer","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E. M.","family":"Herman","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Skarzynski","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2491-4064","authenticated-orcid":false,"given":"Jing","family":"Chang","sequence":"additional","affiliation":[{"name":"2Department of Immunology and Microbiology, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Keyvanfar","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicent","family":"Butera","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Blackburn","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Vire","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Maric","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"5Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-3665","authenticated-orcid":false,"given":"Constance M.","family":"Yuan","sequence":"additional","affiliation":[{"name":"5Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Eckhaus","sequence":"additional","affiliation":[{"name":"6Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Soto","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Z. H.","family":"Farooqui","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Taylor","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[{"name":"2Department of Immunology and Microbiology, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2025032015213699900_bib1","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-based cancer therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"issue":"2","key":"2025032015213699900_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2025032015213699900_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1073\/pnas.85.1.208","article-title":"Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes","volume":"85","author":"Tedder","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025032015213699900_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20 years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025032015213699900_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaut.2017.06.002","article-title":"Direct targeting of cancer cells with antibodies: what can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?","volume":"85","author":"Golay","year":"2017","journal-title":"J\u00a0Autoimmun"},{"issue":"12","key":"2025032015213699900_bib6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2025032015213699900_bib7","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"9","key":"2025032015213699900_bib8","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1074\/jbc.M114.593806","article-title":"Activatory and inhibitory Fc\u03b3 receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain","volume":"290","author":"Vaughan","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"2025032015213699900_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fc\u03b3-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2025032015213699900_bib10","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"2025032015213699900_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12885-015-1041-3","article-title":"Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients","volume":"15","author":"Suzuki","year":"2015","journal-title":"BMC Cancer"},{"issue":"10","key":"2025032015213699900_bib12","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2025032015213699900_bib13","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.4049\/jimmunol.181.11.8120","article-title":"Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes","volume":"181","author":"Beum","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"17","key":"2025032015213699900_bib14","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood-2012-12-473744","article-title":"Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab","volume":"122","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2025032015213699900_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1352458513494488","article-title":"Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis","volume":"20","author":"Zhang","year":"2014","journal-title":"Mult Scler"},{"issue":"7","key":"2025032015213699900_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2025032015213699900_bib17","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025032015213699900_bib18","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","article-title":"Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells","volume":"187","author":"Beum","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2025032015213699900_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025032015213699900_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9747","key":"2025032015213699900_bib21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"9980","key":"2025032015213699900_bib22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"2025032015213699900_bib23","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025032015213699900_bib24","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.4049\/jimmunol.1103693","article-title":"Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients","volume":"188","author":"Beurskens","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"2025032015213699900_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molimm.2017.01.004","article-title":"Complement's hidden arsenal: New insights and novel functions inside the cell","volume":"84","author":"Liszewski","year":"2017","journal-title":"Mol Immunol"},{"issue":"1","key":"2025032015213699900_bib26","first-page":"33","article-title":"Complement component C3 - the \"Swiss army knife\" of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol Res"},{"issue":"9","key":"2025032015213699900_bib27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"issue":"3","key":"2025032015213699900_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/antib9030045","article-title":"How do mAbs make use of complement to kill cancer cells: the role of Ca2+","volume":"9","author":"Taylor","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"2025032015213699900_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.celrep.2012.02.003","article-title":"Assembly and regulation of the membrane\u00a0attack complex based on structures of C5b6 and sC5b9","volume":"1","author":"Hadders","year":"2012","journal-title":"Cell Rep"},{"key":"2025032015213699900_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I: molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"2025032015213699900_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","article-title":"Membrane attack by complement: the assembly and biology of terminal complement complexes","volume":"51","author":"Tegla","year":"2011","journal-title":"Immunol Res"},{"issue":"8","key":"2025032015213699900_bib32","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/eji.201041204","article-title":"Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca2+ influx and induces streamers","volume":"41","author":"Beum","year":"2011","journal-title":"Eur J Immunol"},{"issue":"3","key":"2025032015213699900_bib33","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4049\/jimmunol.135.3.2005","article-title":"Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and\/or complement activation","volume":"135","author":"Ross","year":"1985","journal-title":"J\u00a0Immunol"},{"issue":"22","key":"2025032015213699900_bib34","doi-asserted-by":"crossref","first-page":"10680","DOI":"10.1073\/pnas.91.22.10680","article-title":"Identification of the complement iC3b binding site in the \u03b22 integrin CR3 (CD11b\/CD18)","volume":"91","author":"Ueda","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025032015213699900_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nri2231","article-title":"Complement driven by conformational changes","volume":"8","author":"Gros","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"52","key":"2025032015213699900_bib36","doi-asserted-by":"crossref","first-page":"19737","DOI":"10.1073\/pnas.0609791104","article-title":"Structural transitions of complement component C3 and its activation products","volume":"103","author":"Nishida","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7116","key":"2025032015213699900_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nature05172","article-title":"Structure of C3b reveals conformational changes that underlie complement activity","volume":"444","author":"Janssen","year":"2006","journal-title":"Nature"},{"issue":"8","key":"2025032015213699900_bib38","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1080\/10428194.2021.1888379","article-title":"Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study","volume":"62","author":"Desai","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025032015213699900_bib39","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Herman","year":"2013","journal-title":"Leukemia"},{"issue":"5367","key":"2025032015213699900_bib40","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1126\/science.280.5367.1277","article-title":"X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2","volume":"280","author":"Nagar","year":"1998","journal-title":"Science"},{"issue":"20","key":"2025032015213699900_bib41","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A\u00a0novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2025032015213699900_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A\u00a0CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025032015213699900_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.leukres.2005.08.016","article-title":"Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma","volume":"30","author":"Tucker","year":"2006","journal-title":"Leuk Res"},{"issue":"3","key":"2025032015213699900_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L","article-title":"Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability","volume":"61","author":"Abe","year":"1988","journal-title":"Cancer"},{"issue":"1","key":"2025032015213699900_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.intimp.2011.11.022","article-title":"Exogenous C3 protein enhances the adaptive immune response to polymicrobial sepsis through down-regulation of regulatory T\u00a0cells","volume":"12","author":"Yuan","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2025032015213699900_bib46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00011-012-0448-4","article-title":"The effect of human complement C3 protein applied at different times in treatment of polymicrobial sepsis","volume":"61","author":"Yuan","year":"2012","journal-title":"Inflamm Res"},{"issue":"1-2","key":"2025032015213699900_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jim.2006.10.007","article-title":"Chimeric rabbit\/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector","volume":"318","author":"Hofer","year":"2007","journal-title":"J\u00a0Immunol Methods"},{"issue":"10","key":"2025032015213699900_bib48","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","article-title":"Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia","volume":"177","author":"Williams","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"2025032015213699900_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/antib9040068","article-title":"Complement activation in the treatment of B-cell malignancies","volume":"9","author":"Zent","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"10","key":"2025032015213699900_bib50","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular cytotoxicity of next-generation CD20 monoclonal antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2025032015213699900_bib51","doi-asserted-by":"crossref","first-page":"jcs237883","DOI":"10.1242\/jcs.237883","article-title":"High-resolution quantification of discrete phagocytic events by live cell time-lapse high-content microscopy imaging","volume":"133","author":"Chu","year":"2020","journal-title":"J\u00a0Cell Sci"},{"issue":"3","key":"2025032015213699900_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-08-1685","article-title":"In\u00a0vivo model of follicular lymphoma resistant to rituximab","volume":"15","author":"Dalle","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025032015213699900_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/antib11030045","article-title":"Fc\u03b3R-mediated trogocytosis 2.0: revisiting history gives rise to a unifying hypothesis","volume":"11","author":"Lindorfer","year":"2022","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"2025032015213699900_bib54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/imr.13159","article-title":"Neutrophils as immune effector cells in antibody therapy in cancer","volume":"314","author":"Behrens","year":"2023","journal-title":"Immunol Rev"},{"issue":"5","key":"2025032015213699900_bib55","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"2025032015213699900_bib56","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fimmu.2020.01066","article-title":"Phagocytosis: our current understanding of a universal biological process","volume":"11","author":"Uribe-Querol","year":"2020","journal-title":"Front Immunol"},{"key":"2025032015213699900_bib57","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3389\/fimmu.2018.02716","article-title":"Structural immunology of complement receptors 3 and 4","volume":"9","author":"Vorup-Jensen","year":"2018","journal-title":"Front Immunol"},{"issue":"18","key":"2025032015213699900_bib58","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1158\/0008-5472.CAN-07-1198","article-title":"A\u00a0novel nonobese diabetic\/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease","volume":"67","author":"Durig","year":"2007","journal-title":"Cancer Res"},{"issue":"10","key":"2025032015213699900_bib59","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"2025032015213699900_bib60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","article-title":"The role of complement in kidney disease","volume":"19","author":"Petr","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"2025032015213699900_bib61","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10292","key":"2025032015213699900_bib62","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2025032015213699900_bib63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2025032015213699900_bib64","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"issue":"6505","key":"2025032015213699900_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"2025032015213699900_bib66","doi-asserted-by":"crossref","first-page":"609941","DOI":"10.3389\/fimmu.2020.609941","article-title":"Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength","volume":"11","author":"Bondza","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2025032015213699900_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/1744666X.2022.2031982","article-title":"Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis","volume":"18","author":"Dalla Costa","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"6176","key":"2025032015213699900_bib68","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"issue":"1","key":"2025032015213699900_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymeth.2013.06.036","article-title":"Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions","volume":"65","author":"Kellner","year":"2014","journal-title":"Methods"},{"key":"2025032015213699900_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr Opin Biotechnol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/12\/1309\/2359156\/blood_bld-2024-024846-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/12\/1309\/2359156\/blood_bld-2024-024846-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T22:00:06Z","timestamp":1742508006000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/12\/1309\/534967\/Potentiating-CD20-monoclonal-antibody-therapy-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,3,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024846","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}